Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer

Oncology Reports

Volumn 27, Issue 6, 2012, Pages 2066-2072

  Yang, Guangdie ^a   Yao, Yinan ^a   Zhou, Jianya ^a   Zhao, Qiong ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Antitumor effect; Epidermal growth factor receptor; Exon 19 mutation; Gefitinib; Icotinib hydrochloride; Non small cell lung cancer

Indexed keywords

BPI 2009H; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; ICOTINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL INVASION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; ENZYME PHOSPHORYLATION; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MIGRATION INHIBITION; MITOSIS INHIBITION; MUTATOR GENE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CROWN ETHERS; HUMANS; LUNG NEOPLASMS; MUTATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84860730675     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1741     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
2. Moran C: Importance of molecular features of non-small cell lung cancer for choice of treatment. Am J Pathol 178: 1940-1948, 2011.
3. Carbone DP and Felip E: Adjuvant therapy in non-small cell lung cancer: future treatment prospects and paradigms. Clin Lung Cancer 12: 261-271, 2011.
4. Wong HL and de Boer RH: Vandetanib for the treatment of non-small cell lung cancer. Exp Opin Pharmacother 12: 2271-2278, 2011.
5. Belani CP, Goss G and Blumenschein G Jr: Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC). Cancer Treat Rev 37: 173-184, 2012.
6. Leung K: 124I-Labeled anti-HER2-specific C6.5 diabody. In: Molecular Imaging and Contrast Agent Database (MICAD) (Internet). National Center for Biotechnology Information (US), Bethesda, MD; 2004-2011, 2011.
7. Gazdar AF: Activating and resistance mutations of EGFR in non-small cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28: S24-S31, 2009.
8. Riely GJ, Politi KA, Miller VA and Pao W: Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 12: 7232-7241, 2006. (Pubitemid 46095394)
9. Fukuoka M, Wu Y, Thongprasert S, et al: Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS). J Clin Oncol 29: 2866-2874, 2011.
10. Eskens FA, Mom CH, Planting AS, et al: A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer 98: 80-85, 2008.
11. Erlichman C, Hidalgo M, Boni JP, et al: Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol 24: 2252-2260, 2006. (Pubitemid 46630654)
12. Mendelsohn J and Baselga J: Epidermal growth factor receptor targeting in cancer. Semin Oncol 33: 369-385, 2006. (Pubitemid 44142736)
13. Zhao Q, Shentu J, Xu N, et al: Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer 73: 195-202, 2011.
14. Xing JZ, Zhu L, Jackson JA, et al: Dynamic monitoring of cytotoxicity on microelectronic sensors. Chem Res Toxicol 18: 154-161, 2005. (Pubitemid 40256233)
15. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004. (Pubitemid 38637993)
16. Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004. (Pubitemid 38720929)
17. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306-13311, 2004. (Pubitemid 39209661)
18. Yarden Y: The EGFR family and its ligands in human cancer signaling mechanisms and therapeutic opportunities. Eur J Cancer 37: S3-S8, 2001.
19. Janmaat ML and Giaccone G: The epidermal growth factor receptor pathway and its inhibition as anticancer therapy. Drugs Today 39: 61-80, 2003. (Pubitemid 37509402)
20. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW and Burgess AW: Epidermal growth factor receptor: mechanisms of activation and signaling. Exp Cell Res 284: 31-53, 2003. (Pubitemid 36331965)
21. Kari C, Chan TO, Rocha de Quadros M and Rodeck U: Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res 63: 1-5, 2003.
22. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957, 2009.
23. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353: 123-132, 2005. (Pubitemid 41058344)
24. Thatcher N, Chang A, Parikh P, et al: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366: 1527-1537, 2005. (Pubitemid 41540110)
25. Keedy VL, Temin S, Somerfield MR, et al: American Society of clinical oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 29: 2121-2127, 2011.
26. Pan Q, Pao W and Ladanyi M: Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn 7: 396-403, 2005. (Pubitemid 41149655)
27. Riely GJ, Pao W, Pham D, et al: Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 12: 839-844, 2006. (Pubitemid 43259866)
28. Felip E and Rosell R: Clinical experience with erlotinib in non-small cell lung cancer. Drugs Today (Barc) 42: 147-156, 2006.
29. Nguyen KS, Kobayashi S and Costa DB: Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 10: 281-289, 2009.
30. Zhou W, Ercan D, Chen L, et al: Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462: 1070-1074, 2009.
31. Yokoyama T, Kondo M, Goto Y, et al: EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification. Cancer Sci 97: 753-759, 2006. (Pubitemid 43983788)
32. Yun CH, Mengwasser KE, Toms AV, et al: The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 105: 2070-2075, 2008. (Pubitemid 351439466)
33. Sos ML, Rode HB, Heynck S, et al: Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Res 70: 868-874, 2010.
34. Chiu HC, Chou DL, Huang CT, et al: Suppression of Stat3 activity sensitizes gefitinib-resistant non-small cell lung cancer cells. Biochem Pharmacol 81: 1263-1270, 2011.
35. Kurtze I, Sonnemann J and Beck JF: KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib. Oncol Rep 25: 1021-1029, 2011.
36. de Lima Lopes G Jr, Segel JE, Tan DS, Do YK, Mok T and Finkelstein EA: Cost-effect- tiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. Cancer 118: 1032-1039, 2012.
37. Costanzo R, Piccirillo MC, Sandomenico C, et al: Gefitinib in non-small cell lung cancer. J Biomed Biotechnol 2011: 815269, 2011.
38. Orton RJ, Sturm OE, Vyshemirsky V, Calder M, Gilbert DR and Kolch W: Computational modelling of the receptor-tyrosinekinase- activated MAPK pathway. Biochem J 392: 249-261, 2005. (Pubitemid 41796513)
39. Freeman-Cook KD, Autry C, Borzillo G, et al: Design of selective, ATP-competitive inhibitors of Akt. J Med Chem 53: 4615-4622, 2010.